Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Other Non-current Assets
Long-term assets not reported separately.
Helix BioPharma Corp.TSX: HBP.TO
Other Non-current Assets · Q3 FY2026 · quarter ended Apr 2026
Other non-current assets remains negative
Q3 FY2026 other non-current assets was CA$0, compared with CA$0 a year earlier.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
CAD · from the balance sheet
- Latest · FY2025
- 0 CAD
- Year-over-year change
- +100.0%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 0 | +100.0% |
| FY2024 | 2024-07-31 | (1K) | — |
| FY2023 | 2023-07-31 | 0 | — |
| FY2022 | 2022-07-31 | 0 | -100.0% |
| FY2021 | 2021-07-31 | 0 | — |
Other Non-current Assets vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Other non-current assets amounts to 0.0% of total assets for HBP.TO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $322.23K USD | -39.2% | -21.2% | 0.2% | |
| Apr 2026 | CA$0 CAD | — | — | 0.0% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Apr 2026 | CA$0 CAD | -100.0% | +0.0% | 0.0% | |
| Peer median (excluding HBP.TO) | — | -69.6% | -10.6% | 0.0% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.